{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:14:31Z","timestamp":1783725271882,"version":"3.55.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01HRS029001"],"award-info":[{"award-number":["R01HRS029001"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methadone and buprenorphine, effective treatments for opioid use disorder (OUD), also provide analgesia for managing pain, which is commonly experienced by patients with OUD. Limited population-based evidence exists comparing pain-related and treatment outcomes for methadone versus buprenorphine among patients with OUD and comorbid pain. The study aims to examine pain-related and treatment outcomes among Medicare patients with comorbid pain and OUD who initiated methadone or buprenorphine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study with target trial emulation using the 100% Medicare data from 2020 to 2023. Participants included patients with comorbid chronic pain and OUD who initiated methadone or buprenorphine. The key dependent variables were pain-related outcomes that included hospitalization and emergency department (ED) visit due to pain, and treatment outcomes that included opioid overdose and all-cause mortality. Outcomes were assessed 1 year following treatment initiation. Intention-to-treat and per-protocol analyses were conducted to estimate incidence rate ratios (IRRs) for pain-related outcomes and opioid overdose and hazard ratios (HRs) for all-cause mortality. For each outcome, we also calculated the adjusted risk difference (aRD) between the methadone and buprenorphine groups. We identified 49,727 eligible Medicare patients (mean [SD] age, 59.0 [11.6] years; 24,538 [49.3%] female and 25,189 [50.7%] male). Of the identified patients, 16,174 (32.5%) initiated methadone solely administered at opioid treatment programs, and 33,553 (67.5%) initiated buprenorphine primarily prescribed at office-based clinics. Compared with buprenorphine, initiation of methadone was associated with lower adjusted incidence rates of pain-related hospitalization (IRR, 0.64 (95% CI [0.58, 0.70];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001); aRD, \u22127.2 (95% CI [\u22128.8 to \u22125.7]) per 1,000 person-years) and ED visit (IRR, 0.87 (95% CI [0.82, 0.92];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001); aRD, \u221210.2 (95% CI [\u221214.4, \u22125.9]) per 1,000 person-years) in per-protocol analyses, with no difference in opioid overdose (IRR, 1.02 (95% CI [0.93,1.10];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.72); aRD, 0.33 (95% CI [\u22121.5, 2.1]) per 1,000 person-years) and all-cause mortality (HR, 1.06 (95% CI, [0.81\u20131.39];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.66); aRD, 1.1 (95% CI [\u22121.3, 1.0]) per 1,000 person-years) rates. Similar results were observed in intention-to-treat analyses. Main study limitations included unmeasured confounders and limited generalizability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This population-based cohort study of Medicare patients with comorbid chronic pain and OUD found that methadone administered at opioid treatment programs is associated with reduced hospitalizations and ED visits for pain-related visits while offering treatment outcomes similar to buprenorphine primarily prescribed at office-based clinics. The favorable pain-related outcomes in patients with methadone should be interpreted with caution, as the finding may reflect differences in the underlying patient population, treatment dosing practices, pharmacological properties, and treatment practice settings, which cannot be measured in Medicare data and merit further investigations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004846","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:29:05Z","timestamp":1774546145000},"page":"e1004846","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-6907","authenticated-orcid":true,"given":"Yu-Jung Jenny","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-5961","authenticated-orcid":true,"given":"Almut G.","family":"Winterstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Fillingim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4998-1167","authenticated-orcid":true,"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-6009","authenticated-orcid":true,"given":"Siegfried","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"pmed.1004846.ref001","doi-asserted-by":"crossref","first-page":"104993","DOI":"10.1016\/j.healthpol.2024.104993","article-title":"An international comparative policy analysis of opioid use disorder treatment in primary care across nine high-income jurisdictions","volume":"141","author":"K Chiu","year":"2024","journal-title":"Health Policy"},{"issue":"9","key":"pmed.1004846.ref002","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamapsychiatry.2016.1390","article-title":"Use of opioid agonist therapy for medicare patients in 2013","volume":"73","author":"A Lembke","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"pmed.1004846.ref003","author":"L Niles","year":"2020"},{"key":"pmed.1004846.ref004","unstructured":"The Department of Health and Human Services, Office of Inspector General. The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern. Available from: https:\/\/www.oversight.gov\/sites\/default\/files\/documents\/reports\/2023-12\/OEI-02-23-00250.pdf"},{"issue":"7","key":"pmed.1004846.ref005","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.1907","article-title":"Medicare payment for opioid treatment programs","volume":"5","author":"CH Nakamoto","year":"2024","journal-title":"JAMA Health Forum"},{"key":"pmed.1004846.ref006","unstructured":"Centers for Medicare and Medicaid Services. Opioid Treatment Programs (OTPs) medicare billing and payment fact sheet [accessed 2025 August 20]. Available from: https:\/\/www.cms.gov\/sites\/default\/files\/2020-12\/ICNMLN8296732_2020_12_OTP_Billing_and_Payment_Print_Friendly_508.pdf"},{"issue":"5","key":"pmed.1004846.ref007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14328","article-title":"Trends in methadone dispensing for opioid use disorder after medicare payment policy changes","volume":"6","author":"EA Taylor","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"pmed.1004846.ref008","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDccon2300275","article-title":"How do i manage acute pain for patients prescribed buprenorphine for opioid use disorder?","volume":"3","author":"S Sandhu","year":"2024","journal-title":"NEJM Evid"},{"issue":"1","key":"pmed.1004846.ref009","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pmn.2019.08.003","article-title":"Managing pain in the setting of opioid use disorder","volume":"21","author":"B St Marie","year":"2020","journal-title":"Pain Manag Nurs"},{"issue":"4","key":"pmed.1004846.ref010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.7326\/ANNALS-24-01917","article-title":"Acute pain management in people with opioid use disorder\u00a0: a systematic review","volume":"178","author":"MJ Buonora","year":"2025","journal-title":"Ann Intern Med"},{"key":"pmed.1004846.ref011","volume-title":"Buprenorphine","author":"R Kumar","year":"2025"},{"key":"pmed.1004846.ref012","volume-title":"Methadone","author":"M Durrani","year":"2025"},{"issue":"1","key":"pmed.1004846.ref013","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1213\/ANE.0000000000003368","article-title":"Lack of evidence for ceiling effect for buprenorphine analgesia in humans","volume":"127","author":"MG Richardson","year":"2018","journal-title":"Anesth Analg"},{"issue":"1","key":"pmed.1004846.ref014","doi-asserted-by":"crossref","first-page":"27241","DOI":"10.52965\/001c.27241","article-title":"Buprenorphine for chronic pain: a safer alternative to traditional opioids","volume":"9","author":"S Dalal","year":"2021","journal-title":"Health Psychol Res"},{"issue":"4","key":"pmed.1004846.ref015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jcph.1999","article-title":"Pain management considerations in patients with opioid use disorder requiring critical care","volume":"62","author":"K Smith","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"pmed.1004846.ref016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds","volume":"3","author":"PJ Whelan","year":"2012","journal-title":"J Neurosci Rural Pract"},{"issue":"1","key":"pmed.1004846.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rapm-2024-106014","article-title":"Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials","volume":"51","author":"TR Hickey","year":"2026","journal-title":"Reg Anesth Pain Med"},{"key":"pmed.1004846.ref018","unstructured":"Substance Abuse and Mental Health Services Administration. Federal opioid treatment standards, 42 CFR Part 8 Final Rule [accessed 2025 August 21]. Available from: https:\/\/www.samhsa.gov\/substance-use\/treatment\/opioid-treatment-program\/42-cfr-part-8"},{"key":"pmed.1004846.ref019","author":"R Chou","year":"2016"},{"key":"pmed.1004846.ref020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11606-020-06256-5","article-title":"Managing acute pain in patients taking medication for opioid use disorder: a rapid review","volume":"35","author":"S Veazie","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"6","key":"pmed.1004846.ref021","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"L Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"pmed.1004846.ref022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction","volume":"32","author":"AM Neumann","year":"2013","journal-title":"J Addict Dis"},{"issue":"5","key":"pmed.1004846.ref023","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jamapsychiatry.2023.0310","article-title":"Association of receipt of opioid use disorder-related telehealth services and medications for opioid use disorder with fatal drug overdoses among medicare beneficiaries before and during the COVID-19 pandemic","volume":"80","author":"CM Jones","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"pmed.1004846.ref024","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"CM Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"pmed.1004846.ref025","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"MA Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"3","key":"pmed.1004846.ref026","doi-asserted-by":"crossref","first-page":"37517","DOI":"10.52965\/001c.37517","article-title":"Buprenorphine and its formulations: a comprehensive review","volume":"10","author":"S Poliwoda","year":"2022","journal-title":"Health Psychol Res"},{"issue":"8","key":"pmed.1004846.ref027","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/add.16175","article-title":"Seasonal, weekly and other cyclical patterns in deaths due to drug poisoning in England and Wales","volume":"118","author":"D Lewer","year":"2023","journal-title":"Addiction"},{"issue":"3","key":"pmed.1004846.ref028","article-title":"Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: a nested case-control study","volume":"19","author":"Y-JJ Wei","year":"2022","journal-title":"PLoS Med"},{"issue":"8","key":"pmed.1004846.ref029","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamainternmed.2024.1733","article-title":"Overdose, behavioral health services, and medications for opioid use disorder after a nonfatal overdose","volume":"184","author":"CM Jones","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"2","key":"pmed.1004846.ref030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"ND Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"pmed.1004846.ref031","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"C Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"25","key":"pmed.1004846.ref032","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"PC Austin","year":"2009","journal-title":"Stat Med"},{"key":"pmed.1004846.ref033","doi-asserted-by":"crossref","first-page":"105937","DOI":"10.1016\/j.cct.2020.105937","article-title":"Adherence-adjustment in placebo-controlled randomized trials: an application to the candesartan in heart failure randomized trial","volume":"90","author":"EJ Murray","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"pmed.1004846.ref034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2014.10.010","article-title":"Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain","volume":"145","author":"A Wachholtz","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"pmed.1004846.ref035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10550887.2019.1690929","article-title":"Randomized clinical trial comparing buprenorphine\/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction","volume":"38","author":"AM Neumann","year":"2020","journal-title":"J Addict Dis"},{"issue":"5","key":"pmed.1004846.ref036","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/dar.12041","article-title":"Correlates of pain in an in-treatment sample of opioid-dependent people","volume":"32","author":"S Nielsen","year":"2013","journal-title":"Drug Alcohol Rev"},{"issue":"21","key":"pmed.1004846.ref037","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder","volume":"332","author":"B Nosyk","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"pmed.1004846.ref038","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Jr Santo T","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"pmed.1004846.ref039","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2015.10.018","article-title":"Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients","volume":"157","author":"KE Dunn","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"pmed.1004846.ref040","volume-title":"Opioid use disorder: evaluation and management","author":"AM Dydyk","year":"2025"},{"issue":"5","key":"pmed.1004846.ref041","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"K Kampman","year":"2015","journal-title":"J Addict Med"},{"issue":"2","key":"pmed.1004846.ref042","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-144-2-200601170-00010","article-title":"Acute pain management for patients receiving maintenance methadone or buprenorphine therapy","volume":"144","author":"DP Alford","year":"2006","journal-title":"Ann Intern Med"},{"issue":"12","key":"pmed.1004846.ref043","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/add.16502","article-title":"Questioning methadone split-dosing for analgesia among hospitalized patients with opioid use disorder","volume":"119","author":"D Terasaki","year":"2024","journal-title":"Addiction"},{"issue":"6","key":"pmed.1004846.ref044","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/jama.2024.11913","article-title":"Treatment approaches for opioid use disorder offered in US substance use treatment facilities","volume":"332","author":"TW Park","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"pmed.1004846.ref045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11916-010-0171-1","article-title":"Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon?","volume":"15","author":"DA Tompkins","year":"2011","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"pmed.1004846.ref046","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36076\/ppj.2011\/14\/145","article-title":"A comprehensive review of opioid-induced hyperalgesia","volume":"14","author":"M Lee","year":"2011","journal-title":"Pain Physician"},{"issue":"1","key":"pmed.1004846.ref047","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1803982","article-title":"Methadone in primary care - one small step for congress, one giant leap for addiction treatment","volume":"379","author":"JH Samet","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"pmed.1004846.ref048","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1176\/appi.ajp.2021.20101548","article-title":"Office-based methadone treatment for opioid use disorder and pharmacy dispensing: a scoping review","volume":"178","author":"D McCarty","year":"2021","journal-title":"Am J Psychiatry"},{"key":"pmed.1004846.ref049","article-title":"Chapter 3B: Methadone","volume-title":"Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families: updated 2021","year":"2018"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:29:17Z","timestamp":1774546157000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004846"}},"subtitle":[],"editor":[{"given":"Louisa","family":"Degenhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004846","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}